Draft Biopharmaceutical Comparability Guideline Marks ICH Foray Into Manufacturing Changes
This article was originally published in The Pink Sheet Daily
Q5E will help industry design a comparability study and understand why the information is needed. FDA will publish a draft for comment by mid-February.
You may also be interested in...
NDA and ANDA pilot programs will help transform the way CMC information is submitted and reviewed by FDA. Office of Generic Drugs' white paper on "question-based review" follows the introduction of an NDA pilot program in mid-July.
“Design Space” is emerging as a pivotal concept in FDA’s effort to integrate its pharmaceutical application review and inspection operations into a new “quality assessment” system. With regulatory flexibility for manufacturing changes in the balance, the agency will be working with industry to refine the concept and its application in drug development and manufacturing.
FDA's seizure of GlaxoSmithKline's Paxil CR and Avandamet is the agency's largest in terms of monetary value, involving $4 bil. worth of product, the agency said